Study to Determine the Impact of Multiple Doses of Rifampin on Single-dose Pharmacokinetics of HCV-796
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00384280|
Recruitment Status : Completed
First Posted : October 6, 2006
Last Update Posted : August 12, 2009
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Drug: Rifampin||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||24 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open Label, 2-period, Sequential Study to Determine the Impact of Multiple Doses of Rifampin on Single-dose Pharmacokinetics of HCV-796|
|Study Start Date :||September 2006|
|Actual Primary Completion Date :||November 2006|
|Actual Study Completion Date :||November 2006|
- To evaluate the effects of multiple oral doses of rifampin on the pharmacokinetic (PK) profile of a single oral dose of HCV-796 in healthy subjects.
- To assess the safety and tolerability of HCV-796 and rifampin when coadministered to healthy subjects.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00384280
|Study Director:||Medical Monitor||Wyeth is now a wholly owned subsidiary of Pfizer|